ImmunityBio Reports Record Q1 Revenue, Strong ANKTIVA Sales, and $381M Cash Position
IBRX has more than doubled off its 52-week low of $1.83.
Summary
ImmunityBio announced strong Q1 2026 financial results, including a 168% year-over-year increase in net product revenue and a significant boost in cash reserves, alongside positive clinical and regulatory advancements for ANKTIVA.
Key Events · Earnings and Guidance · IBRX
-
Record Q1 2026 Net Product Revenue
Reported $44.2 million in net product revenue, a 168% increase year-over-year compared to Q1 2025 and a 15% sequential increase from Q4 2025, driven by strong ANKTIVA sales.
-
Strengthened Cash Position
Ended Q1 2026 with $380.9 million in cash, cash equivalents, and marketable securities, up from $242.8 million at year-end 2025, largely due to $223.9 million provided by financing activities.
-
ANKTIVA Regulatory Expansion
ANKTIVA is now approved or authorized across five regulatory jurisdictions (approximately 34 countries), including its first approval in Asia by Macau, and achieved commercial availability in MENA.
-
Clinical Trial Progress
The pivotal BCG-naïve CIS trial (QUILT-2.005) is fully enrolled, with an sBLA submission on track for 2026.
Analysis · IBRX · Life Sciences
ImmunityBio's Q1 2026 results demonstrate robust commercial momentum for ANKTIVA, with substantial revenue growth and unit sales increases. The company significantly strengthened its cash position through financing activities, providing a longer runway for operations and clinical development. Positive updates on the pivotal BCG-naïve NMIBC trial and expanded NCCN recommendations for ANKTIVA further de-risk future growth and market adoption. While the GAAP net loss increased due to non-cash fair value adjustments related to stock price appreciation and a one-time write-off, the underlying operational performance and cash generation are strong, indicating a positive trajectory for the company.
At the time of this filing, IBRX was trading at $8.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $1.83 to $12.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.